Surgical treatment of non-functioning pancreatic islet cell tumors.

Kouvaraki MA, Solorzano CC, Shapiro SE, Yao JC, Perrier ND, Lee JE, Evans DB
J Surg Oncol. 2005 89 (3): 170-85

PMID: 15719379 · DOI:10.1002/jso.20178

Pancreatic endocrine tumors (PETs) are rare neoplasms originating from the amine precursor uptake and decarboxylation (APUD) stem cells. Although the majority of PETs are sporadic, they frequently occur in familial syndromes. PETs may cause a variety of functional syndromes or symptoms of local progression if they are non-functional. General neuroendocrine tumor markers are highly sensitive in the diagnostic assessment of a PET. Imaging studies for tumor localization and staging include computer tomography (CT) scan, magnetic resonance imaging (MRI), In(111)-octreotide scan, MIBG, and endoscopic ultrasonography (EUS). Treatment of PETs often requires a multi-modality approach; however, surgical resection remains the only curative therapy for localized (non-metastatic) disease. Treatment of metastatic disease includes biologic agents, cytotoxic chemotherapy, and liver-directed therapies.

(c) 2005 Wiley-Liss, Inc.

MeSH Terms (14)

Antineoplastic Combined Chemotherapy Protocols Biomarkers, Tumor Carrier Proteins Catheter Ablation Combined Modality Therapy Cytoskeletal Proteins Humans Interferon-alpha Liver Transplantation Molecular Chaperones Multiple Endocrine Neoplasia Type 1 Neuroendocrine Tumors Pancreatic Neoplasms Somatostatin

Connections (1)

This publication is referenced by other Labnodes entities: